AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Kalkine: Is Nanosonics (ASX:NAN) Staying Resilient Despite Weak Price Trends?
June 03, 2025 02:33 PM AEST| By Team Kalkine MediaHighlights,Nanosonics operates within the healthcare sector and is listed on the ASX 200,The company’s return on equity aligns with broader industry benchmarks,Profits are being retained and reinvested, supporting earnings growth,Nanosonics Limited (...
Kalkine: ASX 200 Biotech Stocks Show Signs of Resilience Despite Choppy May
June 03, 2025 02:25 PM AEST| By Team Kalkine MediaHighlights,MedAdvisor and Dimerix record strong market cap increases,Emvision and Paradigm advance pivotal clinical trials,Select companies complete capital raisings amid funding challenges,The Australian biotechnology sector, part of the broader,ASX...
Kalkine: ASX 200 Biotech Stock Recce Pharmaceuticals Advances After Capital Raise Completion
June 03, 2025 01:57 PM AEST| By Team Kalkine MediaHighlights,Recce Pharmaceuticals Ltd (ASX:RCE) completes shortfall placement to finalise broader capital raising initiative,Proceeds to fund key clinical programs focused on antibiotic-resistant infection treatments,Trials include diabetic foot infec...
Race Oncology Plans Investor Engagement Drive in June with ASX300 Spotlight
June 02, 2025 04:30 PM AEST| By Team Kalkine MediaHighlights,Race Oncology (RAC) to present at June investor events,Key updates on lead asset bisantrene (RC220) to be shared,Brisbane investor briefing scheduled for June 27,Race Oncology (ASX:RAC), a clinical-stage biotechnology company focused on pr...
Kalkine| ASX 200 Biotech Stock Imugene Expands Bowel Cancer Vaccine Trial to Australia
June 02, 2025 02:59 PM AEST| By Team Kalkine MediaHighlights,Imugene Ltd (ASX:IMU, OTC:IUGNF) initiates Australian enrolment for its Phase II Neo-POLEM study,The trial assesses PD1-Vaxx immunotherapy for a genetically distinct form of colorectal cancer,Conducted in partnership with leading cancer re...
Orthocell CEO Reaches EY Entrepreneur Finals as ASX 200 Health Sector Advances
June 02, 2025 02:47 PM AEST| By Team Kalkine MediaHighlights,Paul Anderson, CEO of Orthocell Ltd (ASX:OCC, OTC:ORHHF), selected as finalist in EY Entrepreneur Of The Year Australia awards,Orthocell strengthens commercial footprint with Remplir™ nerve repair device and global distribution deals,ASX 2...
Kalkine: Imugene Expands Global Cancer Vaccine Trial, Adding Momentum to ASX200 Biotech Landscape
June 02, 2025 11:43 AM AEST| By Team Kalkine MediaHighlights,Imugene,activates Australian site for Phase II bowel cancer vaccine trial,PD1-Vaxx targets hard-to-treat genetic subtype of colorectal cancer,Study focuses on pre-surgical immune response and long-term outcomes,Imugene Ltd (ASX:IMU) has ma...
Kalkine: Opthea Board Shake-Up Amid Trial Setback and Workforce Cuts: Impact on ASX200 Landscape
June 02, 2025 10:35 AM AEST| By Team Kalkine MediaHighlights,Four,Opthea,directors exit after clinical trial setback,Company slashes workforce by 65% amid,restructuring,Trading,remains,suspended on ASX and Nasdaq,Biotech company,Opthea (ASX:OPT),is undergoing major changes after a significant clinic...
Kalkine: Opthea Board Shake-Up: Director Exodus After Clinical Trial Failure Hits ASX200 Biotech (ASX:OPT)
June 02, 2025 10:29 AM AEST| By Team Kalkine MediaHighlights,Four directors resign from,Opthea,amid clinical trial failure,OPT-302 trial setbacks raise solvency concerns,Ongoing talks continue with primary funders,In a major development impacting the Australian biotech landscape, Opthea Ltd (ASX:OPT...
Kalkine: Beamtree’s Strategic UK Move Boosts Global Footprint with NHS Partnership
May 30, 2025 03:51 PM AEST| By Team Kalkine MediaHighlights,Beamtree partners with NHS Confederation for UK hospital analytics,Launch of Evolve Collaborative planned by late 2025,$1.5M investment to drive expansion and innovation,Healthcare data specialist Beamtree Holdings (ASX:BMT) is taking a bo...
Kalkine| ASX 200 Healthcare Stock Ramsay Soars After Strategic Board Appointment
May 30, 2025 03:28 PM AEST| By Team Kalkine MediaHighlights,Ramsay Health Care (ASX:RHC) appoints Craig Drummond as Non-Executive Director, effective from July,Market responds with strong share movement amid positive sentiment in the healthcare sector,Broader transformation and governance focus ref...
Kalkine| ASX 200 Biotech Stock Recce Pharmaceuticals (ASX:RCE) Secures China Patent for Antibacterial Advancements
May 30, 2025 02:20 PM AEST| By Team Kalkine MediaHighlights,Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) receives patent grant in China for RECCE 327 and RECCE 529,Patent strengthens global protection covering use, administration, and manufacturing methods,Company progresses with trials across So...
Recce Pharmaceuticals’ China Patent Win Bolsters Antibacterial Strategy Amid Expanding ASX200 Opportunities
May 30, 2025 01:36 PM AEST| By Team Kalkine MediaHighlights,Recce secures China patent for RECCE 327 and RECCE 529,Phase III trials underway in Asia and planned in the US,Strategic move aligns with ASX200 index growth outlook,Recce Pharmaceuticals Ltd (ASX:RCE) has taken a significant step forward...
Kalkine: Prescient’s PTX-100 Enters Phase 2A Trial for Rare Lymphoma, Boosting ASX200 Biotech Momentum
May 30, 2025 01:31 PM AEST| By Team Kalkine MediaHighlights,Prescient begins Phase 2A trial of PTX-100 for rare lymphoma,Drug shows promising safety and response in earlier studies,Orphan and fast track FDA designations could speed development,Prescient Therapeutics (ASX:PTX) has officially commenc...
Imugene (ASX:IMU) Strengthens Clinical Leadership With New CMO Amid ASX200 Push
May 30, 2025 11:26 AM AEST| By Team Kalkine MediaHighlights,Imugene,names Dr John Byon as new Chief Medical Officer,Dr Byon brings vast experience in cancer immunotherapy,Clinical pipeline advancement aims to boost treatment options,Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, h...
Kalkine | Healius Limited (ASX:HLS) Slides Sharply Amid Revenue Concerns and Broader ASX 200 Movements
May 29, 2025 04:11 PM AEST| By Team Kalkine MediaHighlights,Healius Limited (ASX:HLS) declines amid ongoing revenue contraction and weak sentiment,Industry comparisons highlight pressure on valuation within the healthcare segment,ASX 200 benchmark shows mixed movements driven by varying sectoral pe...
Emyria’s (ASX:EMD) Breakthrough PTSD Results and ANU Partnership Highlight Innovation in Mental Health Care
May 29, 2025 03:55 PM AEST| By Team Kalkine MediaHighlights,63% of PTSD patients showed no further diagnosis criteria,Emyria partners with ANU to develop mental health care models,Strong positioning in innovative ASX300 healthcare space,Emyria (ASX:EMD), a clinical-stage biotech company, has shared...
Noxopharm's HERACLES Trial Receives Green Light, Boosting Momentum Within ASX300
May 29, 2025 03:42 PM AEST| By Team Kalkine MediaHighlights,HERACLES trial approved for SOF-SKN™ in Australia,Strategic focus on chronic inflammatory conditions,Operational setup begins with expert clinical team,Noxopharm Limited (ASX:NOX) has achieved a major milestone with the approval of its HER...
ASX 200 Healthcare Spotlight: RMD Shares Trade Below Historical Multiples
May 29, 2025 03:08 PM AEST| By Team Kalkine MediaHighlights,ResMed CDI (ASX:RMD) operates within the healthcare sector and maintains a dual listing on the ASX and NYSE,RMD shares reflect a lower price-to-sales ratio compared to historical averages, supported by revenue growth,The company provides C...
Invion’s INV043 Shows Promise in Skin Cancer Treatment as ASX200 Health Innovation Gains Momentum
May 29, 2025 02:51 PM AEST| By Team Kalkine MediaHighlights,INV043 shows no adverse events in Phase I/II NMSC trial,Treatment highlights diagnostic potential through fluorescence,Phase II to refine treatment strategy with adjusted dosage,Australian biotech company Invion (ASX:IVX) has shared encour...
Advertise your brand on Kalkine Media